Press Release Archive
Press Releases
June 2021
06.01.2021 Partnerships IMI SOPHIA PARTNERS WITH MACCABI’S RESEARCH AND INNOVATION CENTER (KSM), PFIZER, AND LAUSANNE UNIVERSITY HOSPITAL TO IMPROVE OBESITY TREATMENT
May 2021
05.28.2021 Covid-19 Vaccines Pfizer and BioNTech Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents 05.28.2021 Responsibility Pfizer Colleagues to Mentor Veterans in Transition to Civilian Life 05.27.2021 Partnerships RefleXion Announces New Additions to Board of Directors and Appoints Audit Committee Chair 05.26.2021 Medicines Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids 05.26.2021 Partnerships The Foundation for the NIH Announces a New Research Initiative to Find Integrated Treatments Across Common Metabolic Diseases 05.24.2021 Research Vaccines Pfizer Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of the Pfizer-BioNTech COVID-19 Vaccine in Older Adults 05.20.2021 Covid-19 Vaccines Pfizer and BioNTech to Supply the European Union With up to 1.8 Billion Additional Doses of COMIRNATY® 05.19.2021 Partnerships Sosei Heptares announces that the third novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trials 05.11.2021 Research Pfizer’s Novel Prediction Model, Derived from Machine Learning, Shows Robust Performance for Identifying Heart Failure Patients At-Risk for Wild-Type Transthyretin Amyloid Cardiomyopathy, a Rare and Life-Threatening Condition 05.10.2021 Covid-19 Vaccines Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents 05.07.2021 Covid-19 Vaccines Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID 19 Vaccine
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.